New trials, publications, preprints and grants on this target, month by month.
Trial
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
11 Nov 2026· PHASE1 · RECRUITING· CTGOV
Publication
The PDE4 inhibitor tanimilast (CHF6001) activates CFTR function in native and in F508del-expressing airway epithelial cells.
5 Nov 2026· European journal of pharmacology· PUBMED
Trial
Roflumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis
30 Oct 2026· PHASE3 · RECRUITING· CTGOV
Publication
The emerging role of PDE4 inhibitors for the treatment of pulmonary fibrosis.
28 Sept 2026· Expert review of clinical pharmacology· PUBMED
Publication
Structural modification of imperatorin affords promising dual AhR/PDE4 modulators for anti-inflammatory therapy.
5 Aug 2026· European journal of medicinal chemistry· PUBMED
Publication
A Comprehensive Review of Phosphodiesterases 4 (PDE4) Inhibitors in Clinical Trials.
23 Jul 2026· Current pharmaceutical design· PUBMED
Publication
Novel Resveratrol Derivatives as Dual PDE4 Inhibitors and Free Radical Scavengers: Rational Design, Synthesis, and Biological Evaluation.
20 Jul 2026· Antioxidants (Basel, Switzerland)· PUBMED
Publication
Precision Modulation of the PDE4 Pathway: The Emerging Role of Nerandomilast in Pulmonary Fibrosis.
16 Jul 2026· The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians· PUBMED
Publication
Safety, pharmacokinetics and pharmacodynamics of TQC3721, an innovative, dual PDE3 and PDE4 inhibitor, in healthy subjects and patients with chronic obstructive pulmonary disease: Randomised, double-blind, placebo-controlled phase I and IIa clinical trials.
14 Jul 2026· British journal of pharmacology· PUBMED
Trial
This Study Evaluates the Safety, Target Engagement, and Preliminary Efficacy of Galunisertib (TGF-βR1/ALK5 Inhibitor)Combined With Nerandomilast (PDE4 Inhibitor) in GREM2-positive ALS, a Biomarker-defined Subgroup Hypothesized to Reflect Heightened TGF-β/SMAD-driven Astrocytic and Fibrotic Signaling
30 Jun 2026· PHASE2_PHASE3 · NOT_YET_RECRUITING· CTGOV
Publication
Efficacy and safety of PDE4 inhibitor monotherapy in adult patients with atopic dermatitis: a systematic review and meta-analysis.
19 Jun 2026· Postepy dermatologii i alergologii· PUBMED
Publication
Comprehensive Pharmacokinetics of the Marine-Derived PDE4 Inhibitor LY104 and Its Major Metabolite M1 in Rats: A Validated LC-MS/MS Method with Sex Comparison, Multiple-Dose, Protein Binding, Metabolic Stability, and Excretion Studies.
15 Jun 2026· Marine drugs· PUBMED
Publication
Pharmacokinetics, Safety and Tolerability of HPP737, a Novel PDE4 Inhibitor, in Healthy Chinese Participants: Phase I Study.
19 May 2026· Drug design, development and therapy· PUBMED
Publication
Natural PDE4 inhibitors from plants: A comprehensive review of discovery, structure-activity relationships, and clinical translation potential.
19 May 2026· European journal of medicinal chemistry· PUBMED
Publication
LS21013A-06, a PDE4 inhibitor, preserves blood-brain barrier integrity in experimental ischemic stroke models through PKA-dependent modulation of LECT2.
25 Apr 2026· European journal of pharmacology· PUBMED
Publication
The effects of the PDE4 inhibitor roflumilast on cognitive performance after a cerebrovascular accident: a double-blind randomized placebo-controlled trial with an open label extension (ROSTMEMA).
24 Apr 2026· Journal of psychopharmacology (Oxford, England)· PUBMED
Publication
Dual targeting of MEK1 and PDE4 by Total lignans from flower buds of Magnolia biondii Pamp. Alleviates atopic dermatitis.
22 Apr 2026· Fitoterapia· PUBMED
Trial
Crisaborole vs Fluticasone Propionate in Mild to Moderate Atopic Dermatitis
17 Apr 2026· NA · COMPLETED· CTGOV
Publication
Variecolactone, a Natural PDE4 Inhibitor from Marine-Derived Talaromyces sp. ZSD-1, Alleviates Amyloid-β Accumulation and mtDNA Dyshomeostasis via cAMP-PKA-CREB Signaling Pathway.
12 Apr 2026· Biomolecules· PUBMED
Publication
SIK1 drives lipid-induced insulin resistance in skeletal muscle by linking TGFβ1-Smad2/3 activation to PDE4-cAMP dysregulation.
17 Mar 2026· Molecular and cellular endocrinology· PUBMED
Publication
PDE4 inhibition in pediatric psoriasis: analysis of the SPROUT study on apremilast.
15 Mar 2026· Expert opinion on pharmacotherapy· PUBMED
Publication
Enhancement of memory network activity in schizophrenia patients by phosphodiesterase-4 (PDE4) inhibitor, roflumilast: A pilot study.
11 Mar 2026· Journal of psychopharmacology (Oxford, England)· PUBMED
Publication
PDE4 inhibitor DC591017 ameliorates pulmonary fibrosis through modulating fibroblasts-epithelial cells-alternatively activated macrophages crosstalk.
28 Feb 2026· European journal of pharmacology· PUBMED
Publication
Discovery of Marine-Inspired Guanidine-Based PDE4 Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease.
25 Feb 2026· Marine drugs· PUBMED
Publication
Discovery of Potent PDE4 Inhibitors with 3(2H)-Pyridazinone Scaffold: Synthesis, In Silico Studies and In Vitro/Vivo Evaluation.
17 Feb 2026· Molecules (Basel, Switzerland)· PUBMED
Publication
Design, synthesis and exploration of cyclic imides as PDE4 inhibitors in psoriasis.
13 Feb 2026· RSC medicinal chemistry· PUBMED
Preprint
PDE4 Inhibitor Apremilast Rebalances Inflammatory Responses to Pseudomonas aeruginosa Infection in CF Rats.
10 Feb 2026· bioRxiv : the preprint server for biology· PUBMED
Publication
Discovery, Synthesis, and Biological Evaluation of Novel Quinoline-Based PDE4 Inhibitors with Potent Anti-Chronic Obstructive Pulmonary Disease Activity.
5 Feb 2026· Journal of medicinal chemistry· PUBMED
Publication
Discovery of Novel Natural Product-Based PDE4 Inhibitors for Ischemic Stroke Treatment without Emetogenicity at Ultra-High Doses.
30 Jan 2026· Journal of medicinal chemistry· PUBMED
Publication
Roflupram Reduces 6-OHDA-Induced Cellular Damage in SH-SY5Y Cells by Inhibiting PDE4.
23 Jan 2026· Journal of integrative neuroscience· PUBMED